a16z backed Tally shuts down and Botox rival Revance goes private in $924M deal 🚀

Exclusive: a16z-backed fintech Tally, which raised $170M in funding, is shutting down after running out of cash

Marketing experts say that a strong name, domain and brand can make a big difference for startups and can be worth paying for — sometimes.

In the last 12 months, Balderton has announced 12 new investments.

(Reuters) -Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought by privately held Crown Laboratories in a deal valued at $924 million, including debt, seeking scale to compete better with rivals in the aesthetic products market. Revance manufactures Daxxify, which competes with AbbVie's Botox, while Tennessee-based Crown makes various skincare and aesthetics products like SkinPen for microneedling and anti-aging cream StriVectin. Revance, which promotes its product to last twice as long as Botox, had initially priced it at a premium.

PayZen aims to make healthcare more affordable by enabling patients to pay their bills in interest and fee-free instalments over time.

The irony was not lost on her. Growing up the daughter of a family obsessed with car racing, Danielle Walsh had become — in her late 20s — the head